Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cessatech ASXSAT:CESSA +3.48%28 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates XSAT:CESSA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Cessatech AS ranks worse than 60.72% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cessatech AS's EBITDA for the
three
months ended in Mar. 2026 was kr-3.76 Mil. Cessatech AS's Revenue for the
three
months ended in Mar. 2026 was kr0.00 Mil. Therefore, Cessatech AS's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
Cessatech AS (XSAT:CESSA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cessatech AS EBITDA Margin % Related Terms
Cessatech AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cessatech AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CESSA vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Cessatech AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cessatech AS EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cessatech AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cessatech AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cessatech AS (XSAT:CESSA) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cessatech AS and its competitors. According to the industry distribution chart, Cessatech AS ranks #572 out of 942 companies in the Biotechnology industry, placing it in the top 60.7%.
Is Cessatech AS's EBITDA Margin % too high?
Cessatech AS's current EBITDA Margin % is 0.00%. Based on the distribution chart, Cessatech AS ranks #572 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cessatech AS has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Cessatech AS's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cessatech AS ranks #572 out of 942 companies for EBITDA Margin %. This places Cessatech AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cessatech AS and its competitors. Cessatech AS's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cessatech AS stock overvalued right now?
Cessatech AS (XSAT:CESSA) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Cessatech AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cessatech AS (XSAT:CESSA), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
28GF Score
Get the complete analysis for XSAT:CESSA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CESSA has been successfully added to your 
